Toronto, Ontario – May 29, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTC Pink®), a medical laser company dedicated to commercializing technology to heal pain and destroy cancer, released its first quarter 2015 financial results today, demonstrating an increase of 2% in revenue year over year. In 2014 and early 2015, Theralase has made dramatic strides in both its Therapeutic Laser Therapy (“TLT”) and Photo Dynamic Therapy (“PDT”) anti-cancer divisions. In the TLT division, Theralase has completed the design and initial manufacture of its next generation TLC-2000 therapeutic laser technology and is currently awaiting final Health Canada approval to launch in Canada. The TLC-2000, with patented Cell SensingTM technology, is able to determine the precise location of injured tissue in a patient based upon their physical characteristics and automatically deliver an optimal dose of healing laser light energy safely and effectively to heal the damaged tissue … Read More
Theralase Grants Stock Options
Toronto, Ontario – May 28, 2015 Theralase Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has granted an aggregate of 4,200,000 stock options to directors and officers at an exercise price of $CAN 0.50 vesting over three years and expiring five years from date of issue. These stock options were granted to directors and officers in compliance with the Company’s 2004 Stock Option Plan approved by the shareholders of the Corporation at the Annual General and Special Meeting held on November 14, 2014. These stock options were granted as a means of rewarding directors and officers for future service to the Corporation, including: Launch of the patented TLC-2000 biofeedback therapeutic laser system with Cell SensingTM technology in 2Q2015 and Commencement of the Health Canada Phase Ib human clinical … Read More
Theralase Presents Latest Scientific Research at 15th International Photodynamic Association World Congress
Toronto, Ontario – May 27, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, presented its latest scientific research at the 15th International Photodynamic Association (“IPA”) World Congress in Rio De Janeiro, Brazil from May 22 to 26, 2015. The latest research details the dramatic increase in targeting and efficacy in the destruction of cancer of Theralase’s lead Photo Dynamic Compound (“PDC”) TLD-1433 when bound to transferrin, in a presentation entitled, “Novel biophysical properties of photosensitizer TLD-1433 upon binding to transferrin” About IPA: The IPA was founded in 1986 and its membership consists of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The purpose of the IPA is to promote the study of diagnosis and treatment using light and … Read More
Theralase to Present at the 2015 Marcum Microcap Conference
Toronto, Ontario – May 26, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 at the Grand Hyatt Hotel in New York City. The Company’s presentation by Roger Dumoulin-White, President & CEO is scheduled to begin at 1:30 pm ET and will be available via live webcast. To access the webcast, please visit http://wsw.com/webcast/marcum3/tltff About the Marcum MicroCap Conference The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from six principal industry sectors and provides investors with the opportunity to meet with management of these companies on a one-on-one basis. Industry … Read More
Treating Chronic Pain with Laser Therapy
Canadians are said to be suffering through a chronic pain epidemic. Pain is a major concern for seniors, many of whom are already coping with health problems associated with age including cognitive issues, a decline in mobility, and other chronic conditions. Approximately 27% of seniors living at home and 38% of seniors in health care institutions suffer some form of chronic pain.1 Pain is an issue which transcends age, not only affecting older Canadians. A Canadian Community Health Survey found that around 1 in 10 Canadians aged 12 to 44 – approximately 1.5 million people – experience some form of chronic pain.2 There are three main types of pain, classified based on where it originates: Somatic pain is caused when receptors in the body surface or musculoskeletal tissues are activated. Pain usually takes the form of a dull ache and is often exacerbated by activity Neuropathic pain originates in the … Read More
Theralase Discovers Anti-Cancer Drug Fluoresces in Tissue
Toronto, Ontario – May 14, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, has discovered that its lead anti-cancer drug, TLD-1433, emits a fluorescent signature when light activated in a Non-Muscle Invasive Bladder Cancer (“NMIBC”) animal model. The advantages of this discovery are three fold: It can be used as a diagnostic tool for the oncologist to detect the presence of cancer cells and micro-metastases too small to be seen by the human eye. It can be used to determine sufficient uptake of TLD-1433 into the cancer cells After light activation, it can determine if the cancer cells that have absorbed the drug have been destroyed. Theralase intends to use this new discovery in the treatment of NMIBC. Clinical Treatment Protocol of NMBIC with Photo Dynamic Therapy: Intravesical installation of TLD-1433 … Read More
Theralase Manufactures High Purity Anti-Cancer Drug
Toronto, Ontario – May 12, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has successfully manufactured its lead, light-activated, anti-cancer drug, TLD-1433, specifically developed for the treatment of cancer, to high purity levels. Drugs intended for in human clinical applications, such as TLD-1433, must be manufactured in accordance with Good Manufacturing Practices (“GMP”) standards. To achieve GMP standards, the normal manufacturing process involves “scaling-up” the production from small quantities to successively larger quantities to optimize the purity and yield of the drug to arrive at a commercial grade product, suitable for human applications. In April 2015, Theralase announced the completion of the manufacture of its lead anti-cancer drug in pre-commercial quantities. The Company has now completed another critical step, optimization of the manufacturing process to produce high … Read More
Theralase Increases Revenue 15% in 2014 Financials
Toronto, Ontario – May 1, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTC Pink®) released its 2014 financial results today, demonstrating an increase of 15% year over year in revenue. In 2014 and early 2015, Theralase has made dramatic strides in both its Therapeutic Laser Therapy (“TLT”) and Photo Dynamic Therapy (“PDT”) anti-cancer divisions. In the TLT division, Theralase has completed the design and initial manufacture of its next generation TLC-2000 therapeutic laser technology and is currently awaiting final Health Canada approval to launch in Canada. The TLC-2000 with patented Cell SensingTM technology is able to determine the precise location of injured tissue in a patient based upon their physical characteristics and automatically deliver an optimal dose of healing laser light energy safely and effectively to heal the damaged tissue faster and more effectively than any other laser system on the market. In the PDT division, … Read More
It’s all in the Wrist: Tips to Avoid Carpal Tunnel Syndrome
In today’s world of texting, tweeting and abundant technology our wrists are in motion almost every waking hour. While minor aches and pains are common for many, for some this repetitive strain can exacerbate a painful condition known as Carpal Tunnel Syndrome. Patients develop Carpal Tunnel Syndrome (CTS) due to an increase in pressure on the median nerve, often due to inflammation of the surrounding tissue within the wrist. This can lead to numbness and tingling in parts of the hand and can be quite painful. With each movement the wrist can become more strained and over time the hand weakens. Although the exact cause of CTS is as yet unknown, the syndrome is known to more commonly affect women and people over the age of 50. In the vast majority of cases, the dominant hand is affected first. Here are some tips to help you avoid CTS: Keep your … Read More
Laser Therapy for Diabetic Neuropathy
Patents living with diabetes are at risk of developing a number of other serious health problems. Prolonged exposure to high blood glucose levels can lead to a myriad of diseases which can affect the eyes, kidneys, teeth, nerves and circulatory system. As many as 60% of diabetics suffer from some form of diabetic neuropathy, which most commonly presents in older patients with a long history of diabetes, or those with high blood pressure or excess body fat. Peripheral neuropathy, one of many forms for diabetic neuropathy, causes numbness and decreased feeling in the feet and toes, pain when walking, and muscle weakness. Charcot Foot, a progressive degenerative condition that affects the joints in the feet, is a frequent result of peripheral neuropathy. Decreases in pain and sensation, combined with decreasing muscle reflexes and control, subject the feet to repeated trauma and injury causing progressive damage to the ligaments, cartilage, and … Read More